

To,

Date: 14.02.2023

|                                                                |                                                                                                                                                 |
|----------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------|
| 1. BSE Limited<br>P.J. Towers, Dalal Street,<br>Mumbai-400 001 | 2. National Stock Exchange of India Limited<br>Exchange plaza, C-1, Block G, Bandra Kurla Complex, Bandra, East,<br>Mumbai-400 051, Maharashtra |
|----------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------|

Dear Sir/Madam,

Sub: Outcome of Board Meeting held on 14.02.2023

Ref: Our Company's letter dated 31.01.2023

Unit: Ortin Laboratories Limited (539287 / ORTINLAB)

With reference to the subject cited, this is to inform the Exchanges that at the meeting of the Board of Directors of Ortin Laboratories Limited held on Tuesday, 14.02.2023 at 3:00 p.m. at the registered office of the Company at D. No.



AN ISO 9001 & A WHO GMP CERTIFIED COMPANY



Ortin Laboratories Ltd. is a leading provider of pharmaceutical and medical products. The company is ISO 9001:2015 certified and is a member of the WHO GMP. Ortin Laboratories Ltd. is a leading provider of pharmaceutical and medical products. The company is ISO 9001:2015 certified and is a member of the WHO GMP.



**MATHESH & RAMANA**  
CHARTERED ACCOUNTANTS

**Independent Auditor's Limited Review Report on unaudited quarterly and year to date  
financial results of the Company**

**To The Board of Directors of  
Ortin Laboratories Limited**

1. We have reviewed the accompanying statement of Unaudited Financial Results of Ortin Laboratories Limited ("the Company") for the quarter ended on 31<sup>st</sup> December, 2022 ("the statement"). This statement is the responsibility of the Company's Management and has been approved by the Company's Board of Directors. Our